Novo Nordisk Raises 2026 Outlook as Wegovy® Pills Exceed 2M Prescriptions

Novo Nordisk delivered stronger-than-expected Q1 2026 results, driven primarily by explosive demand for its newly launched Wegovy® oral formulation, prompting the Danish pharmaceutical giant to raise its full-year guidance. The company reported adjusted operating profit of DKK 32,858 million, bolstered by reported sales growth of 32% at constant exchange rates (CER), though adjusted sales declined 4% due to pricing pressures that were more than offset by blockbuster volume expansion in the company's critical GLP-1 segment.

The standout performer was undoubtedly the Wegovy® pill, which launched in the United States in January 2026 and rapidly gained traction among patients and healthcare providers. The oral formulation accumulated more than 1.3 million prescriptions during Q1 alone and has already surpassed 2 million total prescriptions since its January launch—a remarkable adoption trajectory that underscores both the massive addressable market for weight-loss therapeutics and the significant competitive advantage of an oral delivery mechanism. Building on this momentum, Wegovy® HD (7.2 mg), the highest-strength formulation, received FDA approval and launched in April, demonstrating a mean weight loss of 20.7% in clinical data, further expanding the product's appeal to patients seeking more aggressive therapeutic outcomes.

Key Financial Performance and Product Momentum

Novo Nordisk's Q1 2026 financial results revealed a complex but ultimately encouraging picture when parsing the various drivers of performance:

• Reported sales growth: 32% at constant exchange rates, significantly outpacing analyst expectations
• Adjusted sales: Declined 4% due to lower realized prices across the portfolio, reflecting increased competition and payer pressure in mature markets
• Operating profit: Adjusted operating profit reached DKK 32,858 million, demonstrating strong operating leverage despite pricing headwinds
• Reported sales driver: A substantial 340B provision reversal contributed meaningfully to reported results, though this represents a one-time benefit rather than operational improvement
• International operations: Grew 6% at constant exchange rates, indicating solid geographic diversification
• GLP-1 segment: Experienced robust volume growth, with Wegovy® pills and existing injectable formulations driving expansion

The 340B provision reversal—a compliance-related accounting benefit—inflated headline sales figures but masks an important underlying trend: adjusted sales contraction of 4%, reflecting pricing compression that has affected the broader GLP-1 market as competition intensifies and payers demand better pricing terms. However, the volume dynamics more than compensated for these price declines, particularly in the high-margin Wegovy® franchise, suggesting that Novo Nordisk is successfully capturing market share through superior product positioning and distribution capabilities.

Market Context: The GLP-1 Gold Rush Intensifies

Novo Nordisk operates in one of the most dynamically competitive and rapidly expanding therapeutic categories in modern pharmaceuticals: the GLP-1 receptor agonist market for weight loss and diabetes management. The company faces formidable competition from Eli Lilly ($LLY), whose Mounjaro (tirzepatide) has become a direct competitor in the weight-loss space following off-label adoption, and Roche ($RHHBY), which acquired Carmot Therapeutics to establish its own GLP-1 footprint.

The shift toward oral formulations represents a critical inflection point in the industry. Injectable GLP-1 therapies, while highly effective, present barriers to adoption including patient preference for oral administration, injection-site reactions, and the inconvenience of regular injections. By successfully launching Wegovy® pills and rapidly scaling to 2 million prescriptions, Novo Nordisk has addressed a fundamental patient need and potentially captured a disproportionate share of newly eligible patients who were previously hesitant about injectable therapy.

The regulatory environment has proven favorable, with the FDA expediting approvals for higher-strength formulations like Wegovy® HD, recognizing the substantial public health opportunity in expanding access to effective weight-loss treatments. Simultaneously, payer coverage has broadened, though with increasing scrutiny around pricing and real-world efficacy, creating both tailwinds and headwinds for manufacturers.

International operations growing 6% at CER suggest that Novo Nordisk is successfully expanding its GLP-1 franchise beyond the United States, though the company's ability to command premium pricing internationally may be more limited than in the domestic market, particularly in price-sensitive European and Asian markets.

Investor Implications: Guidance Raise Signals Confidence

The company's decision to raise its 2026 full-year guidance is a powerful signal of confidence in the sustainability of Wegovy® pill demand and profitability. For equity investors in Novo Nordisk (which trades on major exchanges), this guidance raise could support stock valuation multiples, particularly if the company demonstrates that strong Wegovy® volumes can be maintained without catastrophic price erosion.

Several key investment considerations emerge from Q1 2026 results:

Revenue Quality Concerns: The 4% adjusted sales decline, despite robust volume growth, indicates that pricing power remains under pressure. If price declines accelerate or volume growth decelerates, the adjusted sales trajectory could deteriorate further. Investors should monitor pricing trends closely, particularly as competition from Eli Lilly ($LLY) intensifies in coming quarters.

Operating Leverage Potential: Strong adjusted operating profit despite pricing headwinds suggests that Novo Nordisk is benefiting from favorable manufacturing costs, improved manufacturing efficiency, and favorable product mix (oral formulations may have superior margins compared to injectables). This operating leverage could expand if volume continues to grow and the company achieves manufacturing scale benefits.

Market Penetration Runway: With 2 million prescriptions in circulation and an estimated addressable market of tens of millions of patients globally, Novo Nordisk appears to be in the early stages of Wegovy® pill penetration. Further geographic expansion and indication expansion (including potential diabetes applications) could drive multi-year growth, supporting long-term valuation multiples.

Competitive Positioning: The successful launch and rapid adoption of Wegovy® pills provides Novo Nordisk with a meaningful product differentiation advantage relative to competitors still relying primarily on injectables. However, Eli Lilly ($LLY) is actively developing oral tirzepatide formulations, so this advantage may be temporary.

Looking Forward: Growth Sustainability Questions

As Novo Nordisk enters the latter half of 2026 with raised guidance and momentum from Wegovy® pills, critical questions remain about the sustainability of growth trajectories and pricing stability. The company will need to demonstrate that it can maintain strong volume growth while managing price declines, expand internationally without facing significant payer pushback, and defend its market position against well-capitalized competitors like Eli Lilly ($LLY) bringing rival products to market.

The launch of Wegovy® HD in April, with its impressive 20.7% mean weight loss, positions Novo Nordisk to capture patients seeking more aggressive therapeutic outcomes and could open doors to higher-priced premium positioning. However, whether payers will reimburse premium pricing for incremental efficacy remains uncertain.

Overall, Q1 2026 results validate the strategic bet on oral GLP-1 formulations and suggest that Novo Nordisk is successfully executing a market expansion strategy that could define the company's growth trajectory for the next several years. The guidance raise reflects management confidence, but investors should remain vigilant regarding pricing trends and competitive dynamics in what has become the most dynamic pharmaceutical market segment in the industry.